These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35953572)

  • 1. COVID rebound is surprisingly common - even without Paxlovid.
    Callaway E
    Nature; 2022 Aug; ():. PubMed ID: 35953572
    [No Abstract]   [Full Text] [Related]  

  • 2. COVID-19 rebound after Paxlovid treatment during Omicron BA.5 vs BA.2.12.1 subvariant predominance period.
    Wang L; Volkow ND; Davis PB; Berger NA; Kaelber DC; Xu R
    medRxiv; 2022 Aug; ():. PubMed ID: 35982673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir.
    Parums DV
    Med Sci Monit; 2022 Oct; 28():e938532. PubMed ID: 36181334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022.
    Malden DE; Hong V; Lewin BJ; Ackerson BK; Lipsitch M; Lewnard JA; Tartof SY
    MMWR Morb Mortal Wkly Rep; 2022 Jun; 71(25):830-833. PubMed ID: 35737591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022.
    Wang L; Berger NA; Davis PB; Kaelber DC; Volkow ND; Xu R
    medRxiv; 2022 Jun; ():. PubMed ID: 35794889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proxalutamide for the treatment of COVID-19 rebound following Paxlovid treatment: Report of four cases and review of the literature.
    Yang DW; Ju MJ; Wang H; Jia YC; Wang XD; Fang H; Fan J
    J Clin Lab Anal; 2023 Apr; 37(7):e24880. PubMed ID: 37088868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An explanation for SARS-CoV-2 rebound after Paxlovid treatment.
    Perelson AS; Ribeiro RM; Phan T
    medRxiv; 2023 Jun; ():. PubMed ID: 37398088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19: A rapid review and meta-analysis.
    Amani B; Amani B
    J Med Virol; 2023 Feb; 95(2):e28441. PubMed ID: 36576379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19.
    Birabaharan M; Martin TCS
    Am J Emerg Med; 2022 Nov; 61():235.e5-235.e6. PubMed ID: 35970690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Paxlovid on in-hospital outcomes and post-COVID-19 condition in adult patients infected with SARS-CoV-2 Omicron variant: A non-randomized controlled clinical trial.
    Xu J; Song J; Xie Z; Yang J; Wu D; Liu F; Zhao Y; Zang H; Zhao Y
    Medicine (Baltimore); 2023 Dec; 102(51):e36714. PubMed ID: 38134107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Appraisal of evidence reliability and applicability of Paxlovid as treatment for SARS-COV-2 infection: A systematic review.
    Zhu CT; Yin JY; Chen XH; Liu M; Yang SG
    Rev Med Virol; 2023 Nov; 33(6):e2476. PubMed ID: 37578892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of Huashi Baidu granule plus Nirmatrelvir-Ritonavir combination therapy in patients with high-risk factors infected with Omicron (B.1.1.529): A multi-arm single-center, open-label, randomized controlled trial.
    Yu Z; Zheng Y; Chen B; Lv J; Zhu X; Shang B; Xv Y; Tao R; Yang Y; Cong J; Li D; Wu H; Qv W; Zhang X; Xv C; Feng H; Yuan W; Gao Y
    Phytomedicine; 2023 Nov; 120():155025. PubMed ID: 37639813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study.
    Liu J; Pan X; Zhang S; Li M; Ma K; Fan C; Lv Y; Guan X; Yang Y; Ye X; Deng X; Wang Y; Qin L; Xia Z; Ge Z; Zhou Q; Zhang X; Ling Y; Qi T; Wen Z; Huang S; Zhang L; Wang T; Liu Y; Huang Y; Li W; Du H; Chen Y; Xu Y; Zhao Q; Zhao R; Annane D; Qu J; Chen D
    Lancet Reg Health West Pac; 2023 Apr; 33():100694. PubMed ID: 36777445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 Rebound After Paxlovid Treatment: A Case Series and Review of Literature.
    Alshanqeeti S; Bhargava A
    Cureus; 2022 Jun; 14(6):e26239. PubMed ID: 35898366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients.
    Alteri C; Fox V; Scutari R; Burastero GJ; Volpi S; Faltoni M; Fini V; Granaglia A; Esperti S; Gallerani A; Costabile V; Fontana B; Franceschini E; Meschiari M; Campana A; Bernardi S; Villani A; Bernaschi P; Russo C; Guaraldi G; Mussini C; Perno CF
    Commun Biol; 2022 Dec; 5(1):1376. PubMed ID: 36522489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Paxlovid Against Omicron Variants of Coronavirus Disease 2019 in Elderly Patients.
    Weng C; Xie R; Han G; Yuan Y; Li S; Wang C; Wang X; Jiang W; Jiang L
    Infect Dis Ther; 2023 Feb; 12(2):649-662. PubMed ID: 36696068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing the use of Paxlovid in clinical practice.
    McCarthy MW
    Drugs Today (Barc); 2022 Nov; 58(11):539-546. PubMed ID: 36422515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of paxlovid in elderly patients infected with SARS-CoV-2 omicron variants: Results of a non-randomized clinical trial.
    Zhong W; Jiang X; Yang X; Feng T; Duan Z; Wang W; Sun Z; Chen L; Nie X; Zhu C; Zhang W; Li Y
    Front Med (Lausanne); 2022; 9():980002. PubMed ID: 36148451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: A retrospective cohort study.
    Qian G; Wang X; Patel NJ; Kawano Y; Fu X; Cook CE; Vanni KMM; Kowalski EN; Banasiak EP; Bade KJ; Srivatsan S; Williams ZK; Todd DJ; Weinblatt ME; Wallace ZS; Sparks JA
    medRxiv; 2022 Oct; ():. PubMed ID: 36324801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic Surveillance of SARS-CoV-2 M
    Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
    mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.